

ASAIO TRANSACTIONS-VOLUME 34

Subject Index

Editors' Note: This index encompasses only the material presented in ASAIO TRANSACTIONS Volume 34, Numbers 1, 2, and 4. Please consult the July-September issue (Vol. 34, No. 3) for an index of the contents of that body of work.

A

- Abdominal viscera, and peritoneal transport during peritoneal dialysis in rat, 912
- Acquired immunodeficiency syndrome, dialysis and, 907
- Acute renal failure. *See* Renal failure, acute
- Acute respiratory failure, 31
 - severe, venovenous perfusion in, 1,014
- Adsorption, filtration and, for temporary hepatic assistance, 969
- Adult extracorporeal carbon dioxide removal, 1,004
- Adult extracorporeal membrane oxygenation, 1,004
 - with surface-heparinized equipment, 1,009
- Adult respiratory distress syndrome
 - acute, severe, venovenous perfusion in, 1,014
 - extracorporeal circulation in, 43
 - 3-step therapy including, 48
 - extracorporeal support in, 1,006
 - single catheter veno-venous membrane lung bypass in, 35
- AIDS, dialysis and, 907
- Alimentation, intraperitoneal, 125
- Allotransplantation, cardiac, 19
- L-Amino acids, conversion of ammonia or urea into, 24
- Ammonia, conversion of, into L-leucine, L-valine, and L-isoleucine, 24
- Anemia, hemolytic, after chloramine exposure in dialysis center (Letter), 1,060
- Anticalcification treatments, effects of, on bioprosthetic heart valves implanted in sheep, 1,027
- ARDS. *See* Adult respiratory distress syndrome
- Arteriovenous hemofiltration. *See* Continuous arteriovenous hemofiltration
- ASAIO Transactions, peer review, 85

B

- Bioartificial liver, hybrid, composed of multiplated hepatocyte monolayers, 972
- Biodegradable polymers, for drug delivery to brain, 945
- Biomaterials. *See also* Valves, bioprosthetic; Vascular prostheses
 - effects on healing and long-term mechanical properties of vascular prostheses, 95
 - inflammatory response to, 101
 - macrophage interactions with, bioresorbable vascular prostheses and, 1,051
- Blood compatibility, and influence of mold properties on surface structure of polyurethane-siloxane block co-polymer, 10
- Bovine pericardial valve, Gabbay-Meadox unicus, reduction of variability in durability of, 1,022
- Brain, drug delivery to, biodegradable polymers for, 945

C

- Calcification, inhibition of, in bioprosthetic heart valves implanted in sheep, 1,027
- CAPD. *See* Continuous ambulatory peritoneal dialysis
- Carbon dioxide
 - chemical extraction of, via modified peritoneal dialysis, 112
 - extracorporeal removal of adult, 1,004
 - for ARDS, 48
- Cardiac allografts, 19
- Cardiac xenografts, 19
- Cardiotomy, circulatory support following, long-term follow-up of survivors of, 116
- Carotid artery vascular grafts, acute thrombus formation on, factors influencing, 916
- Catheters
 - diameter variability of, clinical implications of, on neonatal CAVH, 108
 - peritoneal, development of, 937
- CAVH. *See* Continuous arteriovenous hemofiltration
- Cells, artificial, containing immobilized multienzyme system and dextran-NAD⁺, in conversion of ammonia or urea into L-amino acids, 24
- Charcoal hemoperfusion, 6, 969
- Children, *See also* Neonatal entries
 - ECMO in, directions for new developments in, 978
 - severe acute respiratory distress syndrome in, venovenous perfusion in, 1,014
- Chloramine, exposure to, in dialysis center, hemolytic anemia after (Letter), 1,060
- Cholesterol removal, by thermofiltration, kinetic analysis of, 965
- Circulation, extracorporeal. *See* Extracorporeal circulation; Membrane oxygenation, extracorporeal
- Circulatory assistance. *See also specific device type*
 - postcardiotomy, long-term follow-up of survivors of, 116
- Co-factor recycling, glucose dehydrogenase for, 24
- Computers, 78
- Continuous ambulatory peritoneal dialysis (CAPD)
 - introduction of, 86
 - new long-term access device for, 930
 - 1987 USA National Registry report on, 150
- Continuous arteriovenous hemofiltration (CAVH), 67
 - neonatal, catheter variability and, 108
 - slow, 63
- Continuous hemodialysis, slow, 59
- Continuous ultrafiltration, slow, 63

D

- Dacron grafts, controlled preclotting and, 921
- DC electric fields, use of, to promote regeneration in mammalian nervous system, 947

Dextran-NAD⁺, immobilized multienzyme system and, artificial cells containing, in conversion of ammonia or urea into L-amino acids, 24
 Dialysis. *See also* Hemodialysis; Peritoneal dialysis in AIDS patients, 907
 maintenance, β -2 microglobulin serum levels in, 923
 outpatient center for, chloramine exposure in, hemolytic anemia after (Letter), 1,060
 shortening of, limitations to, 1
 Dopamine, intracerebroventricular infusion of, in rodents and primates, 951
 Drug delivery
 to brain, biodegradable polymers for, 945
 permanently implanted infusion devices for, 934
 Durability, of heart valve bioprostheses, reduction of variability in, 1,022
 Duraphase penile prosthesis, 996

E

ECCO₂R. *See* Carbon dioxide, extracorporeal removal of
 ECMO. *See* Membrane oxygenation, extracorporeal
 Electric fields, DC, and regeneration in mammalian nervous system, 947
 Equipment, surface-heparinized, adult ECMO and, 1,009
 Erectile dysfunction. *See* Impotence
 Extracorporeal carbon dioxide removal. *See* Carbon dioxide, extracorporeal removal of
 Extracorporeal circulation, in adult respiratory failure, 43
 Extracorporeal membrane oxygenation. *See* Membrane oxygenation, extracorporeal

F

Feeding, intraperitoneal, 125
 Filtration, adsorption and, for temporary hepatic assistance, 969
 Fulminant hepatic failure, orthotopic liver transplantation for, 959

G

Gabbay-Meadox unicuspid bovine pericardial valve, durability of, reduction of variability in, 1,022
 Glucose dehydrogenase, for co-factor recycling, 24
 Gold nucleus density distribution, 10
 Grafts
 allografts, cardiac, 19
 vascular. *See* Vascular prostheses
 xenografts, cardiac, 19

H

Heart, transplantation of, 19
 Heart valves. *See* Valves, prosthetic
 Hemodialysis. *See also* Dialysis
 continuous, slow, 59
 high efficiency, clinical aspects of, 56
 Hemofiltration, continuous, arteriovenous. *See* Continuous arteriovenous hemofiltration
 Hemolytic anemia, after chloramine exposure, in dialysis center (Letter), 1,060
 Hemoperfusion, charcoal, 6, 969
 Heparinization of surfaces, adult ECMO and, 1,009
 Hepatic assistance, temporary, 958
 adsorption and filtration technique for, 969

Hepatic failure, fulminant and subacute, orthotopic liver transplantation for, 959
 Hepatocytes
 monolayer cultures of, multiplated, hybrid bioartificial liver composed of, 972
 temporary liver support and, 958
 HIV, dialysis and, 907
 Hybrid bioartificial liver, composed of multiplated hepatocyte monolayers, 972
 Hypertonic peritoneal dialysis, estimation of lymphatic absorption and intraperitoneal volume during (Letter), 82

I

Immunodeficiency, acquired, dialysis and, 907
 Implants
 artificial urinary sphincter, 1,002
 inflammatory response to, 101
 permanent, of drug-infusion devices, 934
 polyurethane percutaneous access device, for peritoneal dialysis, 941
 Impotence, 986
 diagnosis and surgical treatment of, 991
 historical perspective on, 987
 penile prostheses for
 inflatable, 994
 mechanical, 996
 Incontinence, 986, 998
 Infants. *See* Children; Neonatal entries
 Inflammatory response to implants, 101
 Insulin delivery, implantable devices for, 148
 Intracerebroventricular infusion of dopamine and its agonists, in rodents and primates, 951
 Intraperitoneal feeding, 125
 Intraperitoneal volume, estimation of, during hypertonic peritoneal dialysis (Letter), 82
In vitro testing, of bioprostheses, 1,033
 L-Isoleucine, conversion of ammonia or urea into, 24

K

Kidney, failure of. *See* Renal failure
 Kinetic analysis, of cholesterol removal by thermofiltration, 965
 Knitted Dacron grafts, controlled preclotting and, 921

L

Leaflets, stress in, and durability of heart valve bioprostheses, 1,022
 L-Leucine, conversion of ammonia or urea into, 24
 Liver
 bioartificial, hybrid, composed of multiplated hepatocyte monolayers, 972
 temporary support of, 958
 adsorption and filtration technique for, 969
 transplantation of, orthotopic, for fulminant and subacute hepatic failure, 959
 Lung. *See also* Carbon dioxide removal, extracorporeal; Membrane oxygenation, extracorporeal; Respiratory failure
 bypass, single catheter veno-venous membrane, in treatment of experimental ARDS, 35
 Lymphatic absorption, estimation of, during hypertonic peritoneal dialysis (Letter), 82

M

- Macrophage-biomaterial interactions, with bioresorbable vascular prostheses, 1,051
- Maintenance dialysis, β -2 microglobulin serum levels in, 923
- Mammalian nervous system, regeneration in, DC electric fields for promotion of, 947
- Membrane oxygenation, extracorporeal, 29
 - acute respiratory failure and, 31
 - adult, 1,004
 - with surface-heparinized equipment, 1,009
 - in adult respiratory failure, 35, 43, 48
 - neonatal, 39
 - national experience with, 140
 - pediatric, directions for new developments in, 978
- Membranes, temporary liver support and, 958
- β -2 Microglobulin, serum levels of, in maintenance dialysis, 923
- Mold properties, influence on surface structure of polyurethane-siloxane block co-polymer, 10
- Monolayer cultures of hepatocytes, multiplated, hybrid bioartificial liver composed of, 972
- Multienzyme system, immobilized, artificial cells containing dextran-NAD⁺ and, in conversion of ammonia or urea into L-amino acids, 24

N

- National CAPD Registry, 1987 report of, 150
- National ECMO Registry, 140
- Neonatal continuous arteriovenous hemofiltration (CAVH), catheter variability and, 108
- Neonatal extracorporeal membrane oxygenation, 39
 - national experience with, 140
- Nervous system, mammalian, regeneration in, DC electric fields for promotion of, 947
- Nutrition, intraperitoneal, 125

O

- Omniphase penile prosthesis, 996
- Orthotopic liver transplantation, for fulminant and subacute hepatic failure, 959
- Outpatient dialysis center, chloramine exposure in, hemolytic anemia after (Letter), 1,060
- Oxygenation, membrane. *See* Membrane oxygenation

P

- Parkinson's disease, and intracerebroventricular infusion of dopamine and its agonists in rodents and primates, 951
- Pediatric patients. *See* Children; Neonatal entries
- Penile prostheses. *See also* Urinary entries; Urology
 - inflatable, 994
 - mechanical, Omniphase and Duraphase designs of, 996
- Percutaneous access, for peritoneal dialysis, 932
 - polyurethane device for, peritoneoscopic implantation of, 941
- Perfusion, venovenous, of adults and children with severe acute respiratory distress syndrome, 1,014
- Pericardial valves. *See* Valves, prosthetic
- Pericardium, bovine, 1,022
- Peritoneal catheters, development of, 937
- Peritoneal cavity, alimentation through, 125
- Peritoneal dialysis. *See also* Continuous ambulatory peritoneal dialysis; Dialysis
 - for acute renal failure, 54
 - hypertonic, estimation of lymphatic absorption and intraperitoneal
 - volume during (Letter), 82
 - modified, chemical extraction of carbon dioxide via, 112
 - percutaneous access for, 932
 - polyurethane device for, peritoneoscopic implantation of, 941
 - peritoneal transport during, minimal importance of hollow viscera to, in rat, 912
- Peritoneoscopic implantation of polyurethane percutaneous access device, for peritoneal dialysis, 941
- PHNO ([+]-4-propyl-9-hydroxynaphthoxacine), intracerebroventricular infusion of, 951
- Polymers, biodegradable, for drug delivery to brain, 945
- Polyurethane percutaneous access device, for peritoneal dialysis, peritoneoscopic implantation of, 941
- Polyurethane-siloxane block co-polymer, surface structure of, influence of mold properties on, 10
- Polyurethane small artery substitutes, 1,047
- Porosity, effect on healing and long-term mechanical properties of vascular prostheses, 95
- Postcardiotomy circulatory support, survivors of, long-term follow-up of, 116
- Preclotting, controlled, simplified technique of, 921
- Preimplantation processes, anticalcification and, 1,027
- Prostheses. *See also* Valves, bioprosthetic; Vascular prostheses
 - inflammatory response to, 101
 - urologic, 986
 - impotence and, 987
 - inflatable, 994
 - mechanical, Omniphase and Duraphase designs of, 996
- Pumps. *See also* Ventricular assist devices
 - implantable, insulin, 148

R

- Regeneration, in mammalian nervous system, use of DC electric fields for promotion of, 947
- Renal failure, acute
 - continuous arteriovenous hemofiltration for, 67
 - continuous versus intermittent therapy for, 54
 - technical aspects of, 61
- Respiratory failure
 - acute, 31
 - severe, venovenous perfusion in, 1,014
 - adult, 35, 43, 48, 1,006
 - neonatal, 39, 140

S

- Sexual dysfunction. *See* Impotence
- Slow continuous hemodialysis, 59
- Slow continuous hemofiltration, 63
- Slow continuous ultrafiltration, 63
- Small diameter vascular prostheses, 88, 1,043, 1,058
 - bioresorbable, macrophage-biomaterial interactions with, 1,051
 - polyurethane small artery substitutes, 1,047
- Sorbents, temporary liver support and, 958
- Subacute hepatic failure, orthotopic liver transplantation for, 959
- Surfaces
 - heparinized, adult ECMO and, 1,009
 - structure of, influence of mold properties on, 10

T

- Testing, *in vitro*, of bioprostheses, 1,033
- Thermofiltration, cholesterol removal by, kinetic analysis of, 965
- Thrombus formation, acute, on carotid artery vascular grafts, 916
- Transplantation. See *specific organ*

U

- Ultrafiltration, continuous, slow, 63
- Urea, conversion of, into L-leucine, L-valine, and L-isoleucine, 24
- Urinary incontinence, 998
- Urinary sphincter, artificial, 1,000
- surgical implantation of, 1,002
- Urology
 - diagnosis and surgical treatment of erectile dysfunction, 991
 - prosthetic devices in, 986
 - impotence and, 987
 - inflatable, 994
 - mechanical, Omniphase and Duraphase designs of, 996

V

- L-Valine, conversion of ammonia or urea into, 24
- Valves, bioprosthetic, 1,021
 - durability of, reduction of variability in, 1,022
 - effects of anticalcification treatments on, in sheep, 1,027
 - future of, 1,031
 - pathologist's perspective on, 1,040
 - in vitro* testing of, 1,033

- Vascular access, long term, permanently implanted devices for, 934
- Vascular prostheses
 - bioresorbable, macrophage-biomaterial interactions with, 1,051
 - carotid artery, acute thrombus formation on, factors influencing, 916
 - controlled preclotting and, 921
 - healing and long-term mechanical properties of, effect of porosity and biomaterial on, 95
 - new materials for, 88
 - small diameter, 88, 1,043, 1,058
 - polyurethane small artery substitutes, 1,047
- Venous access, long term, permanently implanted devices for, 934
- Venovenous membrane lung bypass, single catheter, in treatment of experimental ARDS, 35
- Venovenous perfusion, of adults and children with severe acute respiratory distress syndrome, 1,014
- Ventilation, mechanical, in ARDS, 1,006
- Ventricular assist devices, weaning from, predictors for, 131
- Viscera, hollow, and peritoneal transport during peritoneal dialysis, 912

W

- Weaning, from ventricular assist devices, predictors for, 131

X

- Xenotransplantation, cardiac, 19

Author Index

A

Agishi, Tetsuzo, 34:958
Anderson, James M., 34:101,
34:1043
Arensman, Robert M., 34:978
Assounga, A., 34:923
Aznar, R., 34:923

B

Bartlett, Robert H., 34:29, 34:67,
34:140,
Beck, Eduardo, 34:48
Bindslev, Lars, 34:1004
Bland, Lee, 34:1060
Borelli, M., 34:35
Bosch, Juan, 34:67
Bourgoignie, Jacques J., 34:907
Bower, John D., 34:125, 34:912
Buur, Tom, 34:78

C

Callow, Allan D., 34:88
Campbell, David B., 34:1004
Canaud, B., 34:923
Casarejos, Maria Jose, 34:945
Chang, Thomas Ming Swi, 34:24
Cilley, Robert E., 34:140
Clark, Richard E., 34:1021
Collins, Allan J., 34:1, 34:56
Connolly, Raymond J., 34:1043
Cornell, Richard G., 34:140
Cruz, Cosme, 34:930
Cutler, Sidney J., 34:150

D

Daly, Benedict D. T., 34:930
Damia, G., 34:43
Denes, Bela, 34:986
de Yebenes, Justo Garcia, 34:945
Drusin, Ronald E., 34:19
Dunea, George, 34:6
Dunn, Irving, 34:78

E

Eberhart, R. C., 34:10
Eidbo, Elling E., 34:1021

F

Fahn, Stanley., 34:945
Favero, Martin S., 34:1060
Ferrans, Victor J., 34:1021
Fisher, Marian., 34:148
Flavier, J. L., 34:923

Friedman, Eli A., 34:85
Fuchinoue, Shouhei, 34:958
Funatsu, Akihiko, 34:958
Funk, James E., 34:108

G

Gabbay, Shlomo, 34:1021
Gattinoni, L., 34:43, 34:1004
Geronemus, Robert P., 34:59, 34:67
Giersiepen, M., 34:1021
Gregory, John G., 34:986
Greisler, Howard, 34:1043
Gu, Kang Fu, 34:24

H

Hamada, Tomonori, 34:958
Hanson, Stephen R., 34:916
Hase, Taiji, 34:958
Hashimura, Etsuro, 34:958
Hermann, Virginia M., 34:930
High, Kane M., 34:1004
Hilbert, Stephen L., 34:1021
Honda, Hiroshi, 34:958

I

Iwatsuki, Shunzaburo, 34:958

J

Jarvis, William R., 34:1060
Jenkins, Randall D., 34:108
Jones, Michael, 34:1021
Jones, Quintus, 34:125, 34:912

K

Kambic, Helen E., 34:1043
Kanter, Kirk R., 34:116, 34:131
Kantrowitz, Adrian, 34:930
Keamy, Mitchell F., 34:1004
Keshaviah, Prakash R., 34:1, 34:61
Kim, S. W., 34:10
Klein, Michael D., 34:39, 34:978
Knatterud, Genell, 34:148
Knott, E., 34:1021
Kofke, W. Andrew, 34:1004
Kolobow, Theodor, 34:31, 34:35,
34:43, 34:1004
Komai, Takashi, 34:958
Kon, Tadamasu, 34:958
Kuhn, Robert J., 34:108
Kumagai, Fumiaki, 34:958

L

Langer, Robert, 34:945, 34:978
Lindblad, Anne S., 34:150

M

Magilligan, Donald J., 34:1021
Malchesky, Paul S., 34:958
McBride, Lawrence R., 34:116,
34:131
McManus, Robert P., 34:19
Meguire, Simon, 34:78
Mena, Maria Angeles, 34:945
Menlove, Ronald L., 34:48
Merrill, Edward W., 34:1043
Michler, Robert E., 34:19
Mion, C., 34:923
Moncrief, Jack W., 34:86
Morris, Alan H., 34:48
Mottaghy, Khosrow, 34:978

N

Nakamura, Keiichi, 34:958
Nolph, Karl D., 34:54, 34:150
Nolte, Stephan H., 34:978
Nomura, Hideaki, 34:958
Nosé, Y., 34:958
Novak, Joel W., 34:150

O

Ota, Kazuo, 34:958

P

Paganini, Emil P., 34:63, 34:67
Pardo, Beatriz, 34:945
Parra, Raul O., 34:986
Paxton, Lamont D., 34:916
Pennell, J. Phillip, 34:907
Pennington, D. Glenn, 34:116,
34:131
Pesenti, A., 34:43, 34:1004
Planch, Angela, 34:125, 34:912
Porter, Christopher H., 34:986
Prato, P., 34:35
Purcell, Michaela H., 34:986

R

Reemtsma, Keith, 34:19
Reul, H., 34:1021
Robinet-Levy, M., 34:923
Rollins, R. James, 34:48
Ronco, Claudio, 34:67
Rose, Eric A., 34:19
Rubin, Jack, 34:125, 34:912

Russell, Garfield B., 34:1004
 Ruzevich, Shelly A., 34:116, 34:131

S

Sadeghi, Ali, 34:19
 Samuels, Larry D., 34:131
 Sauvage, Lester R., 34:921
 Schneider, Peter A., 34:916
 Schoen, Frederick J., 34:1021
 Sevastianov, V. I., 34:10
 Shah, Bharat S., 34:112
 Slingeneyer, A., 34:923
 Smith, Craig R., 34:19
 Snedecor, Sandy M., 34:140
 Snider, Michael T., 34:1004
 Spatola, R., 34:35
 Stablein, Donald M., 34:150
 Starzl, Thomas E., 34:958
 Stieber, Andrei C., 34:958

Swartz, Marc T., 34:116, 34:131
 Swartz, Richard, 34:67

T

Takeyama, Yoshifumi, 34:958
 Teraoka, Satoshi, 34:958
 Termuhlen, David F., 34:116,
 34:131
 Timm, Gerald W., 34:986
 Tipple, Margaret A., 34:1060
 Toomasian, John M., 34:140
 Torem, Shlomo, 34:916
 Tsuburaya, Toshihiko, 34:958
 Tsuno, K., 34:35
 Twardowski, Zyblut J., 34:930

U

Uchino, Junichi, 34:958

W

Wallace, C. Jane, 34:48
 Weber, Thomas R., 34:978
 Welch, Herbert, 34:1021
 Werynski, Andrzej, 34:958
 White, Rodney A., 34:95
 Williams, Dennis R., 34:1004

Y

Yamashita, Masato, 34:958
 Yasuda, Hirotsugu, 34:916
 Yeager, Anson, 34:88

Z

Zanakis, Michael F., 34:945

STATEMENT OF OWNERSHIP, MANAGEMENT AND CIRCULATION (Act of August 12, 1970: Section 3685. Title 39 United States Code) Date of Filing—October 1, 1988; Title of Publication—ASAIO Transactions; Publication No.—457330; Frequency of Issue—Quarterly; Annual Subscription Price—\$95.00; Location of Known Office of Publication—Downsville Pike, Route 3, Box 20-B, Hagerstown, MD 21740; Location of the Headquarters or General Business Offices of the Publisher—East Washington Square, Philadelphia, PA 19105; Publisher—American Society for Artificial Internal Organs, Inc., East Washington Square, Philadelphia, PA 19105; Editor—Eli A. Friedman, SUNY Health Science Center at Brooklyn, 450 Clarkson Avenue, Brooklyn, NY 11203; Managing Editor—Theresa Rosen, East Washington Square, Philadelphia, PA 19105; Owner—American Society for Artificial Internal Organs, Inc., National Office ASAIO, PO Box C, Boca Raton, FL 33432; Known Bondholders, Mortgagees, and other security holders owning or holding 1 percent or more of total amount of bonds, mortgages, or other securities—None. A. Total no. copies printed (*net press run*), average 2,875, actual 3,000; B. Paid circulation 1. Sales through dealers and carriers, street vendors and counter sales, average none, actual none; 2. Mail subscriptions, average 2,257, actual 2,230; C. Total paid circulation, average 2,257, actual 2,230; D. Free distribution by mail, carrier or other means. Samples complimentary, and other free copies, average 158, actual 11; E. Total distribution (*sum of C and D*), average 2,415, actual 2,241; F. Copies not distributed 1. Office use, leftover, unaccounted, spoiled after printing, average 460, actual 759; 2. Returns from news agents, none; G. Total (*sum of E and F—should equal net press runs shown in A*), average 2,875, actual 3,000. I certify that the statements made by me above are correct and complete. Tish Packman, *Circulation Manager*.

